Percutaneous treatment options for acute pulmonary embolism: a clinical consensus statement by the ESC Working Group on Pulmonary Circulation and Right Ventricular Function and the European Association of Percutaneous Cardiovascular Interventions.
Journal
EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology
ISSN: 1969-6213
Titre abrégé: EuroIntervention
Pays: France
ID NLM: 101251040
Informations de publication
Date de publication:
07 Oct 2022
07 Oct 2022
Historique:
pubmed:
17
9
2022
medline:
12
10
2022
entrez:
16
9
2022
Statut:
epublish
Résumé
There is a growing clinical and scientific interest in catheter-directed therapy (CDT) of acute pulmonary embolism (PE). Currently, CDT should be considered for patients with high-risk PE, in whom thrombolysis is contraindicated or has failed. Also, CDT is a treatment option for initially stable patients in whom anticoagulant treatment fails, i.e., those who experience haemodynamic deterioration despite adequately dosed anticoagulation. However, the definition of treatment failure (primary reperfusion therapy or anticoagulation alone) remains an important area of uncertainty. Moreover, several techniques for CDT are available without evidence supporting one over the other, and variation in practice with regard to periprocedural anticoagulation is considerable. The aim of this position paper is to describe the currently available CDT approaches in PE patients and to standardise patient selection, the timing and technique of the procedure itself as well as anticoagulation regimens during CDT. We discuss several clinical scenarios of the clinical evaluation of the "efficacy" of thrombolysis and anticoagulation, including treatment failure with haemodynamic deterioration and treatment failure based on a lack of improvement. This clinical consensus statement serves as a practical guide for CDT, complementary to the formal guidelines.
Identifiants
pubmed: 36112184
pii: EIJ-D-22-00246
doi: 10.4244/EIJ-D-22-00246
pmc: PMC10241264
pii:
doi:
Substances chimiques
Anticoagulants
0
Fibrinolytic Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e623-e638Références
BMJ. 2020 May 20;369:m1501
pubmed: 32434791
Eur Respir J. 2018 Jan 18;51(1):
pubmed: 29348184
EGEMS (Wash DC). 2017 Jun 14;5(1):12
pubmed: 29930960
Eur Heart J. 2020 Jan 21;41(4):543-603
pubmed: 31504429
Eur J Haematol. 2015 Dec;95(6):489-97
pubmed: 26109174
EuroIntervention. 2018 Nov 20;14(10):1136-1143
pubmed: 30082262
Hosp Pract (1995). 2014 Feb;42(1):31-7
pubmed: 24566594
Postepy Kardiol Interwencyjnej. 2021 Mar;17(1):109-111
pubmed: 33868426
Eur Heart J. 2020 Jan 21;41(4):522-529
pubmed: 31102407
Int J Cardiol. 2019 Jul 15;287:106-110
pubmed: 30846255
Am J Cardiol. 2017 Nov 1;120(9):1653-1661
pubmed: 28882336
J Invasive Cardiol. 2020 Nov;32(11):412-416
pubmed: 33130592
Eur Heart J. 2018 Jan 7;39(2):119-177
pubmed: 28886621
Catheter Cardiovasc Interv. 2022 Mar;99(4):1345-1355
pubmed: 35114059
Phys Med Biol. 2008 Dec 7;53(23):6837-47
pubmed: 19001697
JACC Cardiovasc Interv. 2021 Feb 8;14(3):319-329
pubmed: 33454291
Neurol Sci. 2022 Feb;43(2):1127-1134
pubmed: 34212264
Crit Care Med. 2021 May 1;49(5):760-769
pubmed: 33590996
Circulation. 2019 Nov 12;140(20):e774-e801
pubmed: 31585051
Circulation. 2011 Dec 13;124(24):2716-24
pubmed: 22082681
Nat Rev Dis Primers. 2018 May 17;4:18028
pubmed: 29770793
Lancet Haematol. 2021 Sep;8(9):e627-e636
pubmed: 34363769
Hematology Am Soc Hematol Educ Program. 2020 Dec 4;2020(1):195-200
pubmed: 33275707
Eur Heart J. 2018 Dec 14;39(47):4196-4204
pubmed: 30137303
Chest. 2016 Dec;150(6):1414-1417
pubmed: 27938758
JACC Cardiovasc Interv. 2019 May 13;12(9):859-869
pubmed: 31072507
JACC Cardiovasc Interv. 2015 Aug 24;8(10):1382-1392
pubmed: 26315743
Vasc Med. 2017 Feb;22(1):44-50
pubmed: 27913777
N Engl J Med. 2014 Apr 10;370(15):1402-11
pubmed: 24716681
EuroIntervention. 2018 Feb 20;13(14):1721-1727
pubmed: 29175770
Catheter Cardiovasc Interv. 2017 Mar 1;89(4):754-760
pubmed: 28145042
Lancet. 1999 Apr 24;353(9162):1386-9
pubmed: 10227218
Heart Lung Circ. 2015 Jan;24(1):46-54
pubmed: 25060976
JACC Cardiovasc Interv. 2018 Jul 23;11(14):1401-1410
pubmed: 30025734
Eur J Intern Med. 2020 Dec;82:76-82
pubmed: 32843290
Circulation. 2016 Jan 5;133(1):98-103
pubmed: 26719388
JACC Cardiovasc Interv. 2021 Jun 28;14(12):1364-1373
pubmed: 34167677
Kardiol Pol. 2021;79(12):1311-1319
pubmed: 34643260
Kardiol Pol. 2019;77(2):228-231
pubmed: 30566224
Chest. 2006 Apr;129(4):1043-50
pubmed: 16608956
EuroIntervention. 2021 Jun 11;17(2):e158-e166
pubmed: 32863245
J Vasc Interv Radiol. 2019 Sep;30(9):1370-1375
pubmed: 31375449
J Vasc Surg Venous Lymphat Disord. 2018 Jul;6(4):530-540
pubmed: 29909859
Circ Cardiovasc Interv. 2021 Jan;14(1):e009611
pubmed: 33356383
Ann Emerg Med. 2013 Mar;61(3):330-8
pubmed: 23306454
Catheter Cardiovasc Interv. 2021 Apr 1;97(5):869-873
pubmed: 33226187
Circulation. 2014 Jan 28;129(4):479-86
pubmed: 24226805
Pol Arch Intern Med. 2021 Jun 29;131(6):568-570
pubmed: 33825418
Curr Vasc Pharmacol. 2018 Jan 26;16(2):179-189
pubmed: 28393706
Vascular. 2018 Apr;26(2):163-168
pubmed: 28828935
Eur Heart J Suppl. 2019 Nov;21(Suppl I):I23-I30
pubmed: 31777454
Stroke. 2019 Oct;50(10):2716-2721
pubmed: 31394994
Am J Med. 2021 Oct;134(10):1260-1264
pubmed: 33631160
J Stroke Cerebrovasc Dis. 2015 Feb;24(2):394-400
pubmed: 25497721
Eur J Heart Fail. 2016 Mar;18(3):226-41
pubmed: 26995592
Anatol J Cardiol. 2021 Dec;25(12):902-911
pubmed: 34866585
Stud Health Technol Inform. 2018;250:187-191
pubmed: 29857426
Chest. 2015 Sep;148(3):667-673
pubmed: 25856269
Am J Cardiol. 2019 Nov 1;124(9):1470-1477
pubmed: 31492420